# An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia

> **NCT01662310** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 201 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01662310
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01662310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01662310, "An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01662310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*